secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001213900-24-005352
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine
--------------------------------------------------------------------------------

- FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.
- FDA indicated proposed study could support approval if clinical endpoint used; company revising protocol accordingly.
- Patient enrollment targeted to begin in summer 2024 at three northeastern U.S. hospitals.
- Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis but not yet for babesiosis; estimated 47,000 patients/year in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/0001213900-24-005352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/ea191960-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-005352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer